Technical indicators for Pfizer and GSK have turned bullish.

Pfizer stock reached a 52-week high, hitting 27.99 USD, marking a significant milestone for the pharmaceutical giant. Over the past year, Pfizer has experienced a positive traject ...

They aren't just "pandemic stocks." ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions. 10 stocks we like ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...